West reports Q2 2026 results and raises full-year guidance
Net sales grew 13.8% to $872.3 million, and the company raised full-year guidance.
See the latest news and media coverage for West. We track all announcements, press releases, and industry mentions in real time, all in one place.
Manufacturer of injectable drug packaging and delivery systems
westpharma.comLast updated
In short: West Pharmaceutical Services raised its annual profit and revenue forecasts following strong second-quarter financial performance in 2026.
Net sales grew 13.8% to $872.3 million, and the company raised full-year guidance.
The transaction closed on July 1, 2026. West retains other SmartDose versions.
The report details progress on renewable energy projects and SBTi-validated climate goals, emphasizing People, Process, and Planet pillars.
He will succeed Eric M. Green, who is retiring, and Robert F. Friel becomes Board Chair.
West Pharmaceutical Services beats Q2 earnings, raises FY guidance, and sees biologics-driven margin gains. Click to read this earnings analysis of WST stock.
On July 23, 2026, Evercore ISI reaffirmed its Outperform rating for West Pharmaceutical Services Inc...
The company delivered a Q2 beat, raised FY guidance, and navigated a cyber incident in its West Vantage segment while transitioning leadership.
West Pharmaceutical Services raised its annual profit and revenue forecasts on Thursday as strong de...
Track West and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to West and other trending companies.